IRIS
ZANGHI', AURORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.227
NA - Nord America 1.134
AS - Asia 1.068
SA - Sud America 283
AF - Africa 25
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.747
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.102
SG - Singapore 517
IE - Irlanda 385
RU - Federazione Russa 280
BR - Brasile 239
CN - Cina 193
IT - Italia 170
HK - Hong Kong 142
VN - Vietnam 106
FR - Francia 88
DE - Germania 77
SE - Svezia 71
FI - Finlandia 48
GB - Regno Unito 36
AR - Argentina 17
IN - India 17
CA - Canada 15
NL - Olanda 15
TR - Turchia 15
BD - Bangladesh 13
IQ - Iraq 11
PL - Polonia 11
MX - Messico 10
EC - Ecuador 8
AT - Austria 7
ES - Italia 7
ID - Indonesia 7
ZA - Sudafrica 7
AU - Australia 6
IR - Iran 6
JP - Giappone 6
PK - Pakistan 6
BE - Belgio 5
CL - Cile 5
EG - Egitto 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
MA - Marocco 4
SA - Arabia Saudita 4
VE - Venezuela 4
AL - Albania 3
CO - Colombia 3
DZ - Algeria 3
PH - Filippine 3
PY - Paraguay 3
RO - Romania 3
UZ - Uzbekistan 3
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
HN - Honduras 2
HR - Croazia 2
JO - Giordania 2
LT - Lituania 2
MD - Moldavia 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
UA - Ucraina 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
TO - Tonga 1
Totale 3.747
Salva come PNG Salva come JPEG
Città #
Dublin 385
San Jose 307
Singapore 196
Ashburn 142
Hong Kong 137
Beijing 100
Chandler 87
Santa Clara 71
Nyköping 70
Lauterbourg 59
Ho Chi Minh City 39
Princeton 39
Helsinki 34
Munich 27
Wilmington 26
São Paulo 25
Los Angeles 24
Dallas 21
Frankfurt am Main 21
Hanoi 19
Moscow 17
Naples 15
New York 15
Turku 14
Assago 12
London 12
Des Moines 11
Hillsboro 10
Milan 10
Rio de Janeiro 10
Rome 10
Warsaw 10
Nuremberg 9
Seattle 9
Falkenstein 8
Kocaeli 8
Chicago 7
Düsseldorf 7
Guangzhou 7
Bari 6
Belo Horizonte 6
Curitiba 6
San Francisco 6
Ankara 5
Biên Hòa 5
Buffalo 5
Council Bluffs 5
Frattamaggiore 5
Paris 5
The Dalles 5
Thái Bình 5
Tokyo 5
Washington 5
Alessandria 4
Brooklyn 4
Cairo 4
Campinas 4
Cedar Knolls 4
Denver 4
Francavilla Fontana 4
Johannesburg 4
Long Beach 4
Montreal 4
Ninh Bình 4
Orem 4
Ottawa 4
Reston 4
Ribeirão Preto 4
San Severo 4
Sorocaba 4
Tehran 4
Toronto 4
Tsuen Wan 4
Ufa 4
Vienna 4
Anápolis 3
Atlanta 3
Brussels 3
Buenos Aires 3
Bắc Ninh 3
Can Tho 3
Caxias do Sul 3
Chennai 3
Contagem 3
Da Nang 3
Guarulhos 3
Haiphong 3
Jiaxing 3
Karachi 3
Las Vegas 3
Lucera 3
Mexico City 3
Norwalk 3
Phoenix 3
Porto Alegre 3
Quito 3
Riyadh 3
Shenzhen 3
Tashkent 3
Tirana 3
Totale 2.267
Salva come PNG Salva come JPEG
Nome #
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 110
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 108
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 95
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 94
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 94
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 91
Can new chemical therapies improve the management of multiple sclerosis in children? 89
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 88
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 87
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 85
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 85
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 83
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 83
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 82
An update on the safety of treating relapsing-remitting multiple sclerosis 79
An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience 76
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study 76
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 75
First-line therapies in Late Onset Multiple Sclerosis: an Italian registry study 74
Management of dysphagia in multiple sclerosis: current best practice 72
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 71
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS 69
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 68
Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV IgG Tests in RRMS to Assess PML Risk 67
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 66
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 65
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 64
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 64
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 63
Myeloid-derived Suppressor Cells and Multiple Sclerosis 62
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience 62
Palliative care in progressive multiple sclerosis 62
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 59
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 59
MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study 58
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer 57
Monocytic myeloid derived suppressor cells in hematological malignancies 55
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 54
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 54
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 53
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 53
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 53
Relapse-associated worsening in a real-life multiple sclerosis cohort: The role of age and pyramidal phenotype 52
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 52
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 52
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 51
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 50
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 50
Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study 49
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 49
Switching therapy: how and why in a real word setting cohort of persons with multiple sclerosis in Catania 49
Multiple sclerosis from onset to secondary progression: a 30-year Italian register study 48
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 48
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 48
Neural precursor cells tune striatal connectivity through the release of IGFBPL1 48
Real-World comparison of reasons for changing treatment to dimethyl-fymarate or teriflunomide in non responders patients with relapsing remitting multiple sclerosis: preliminary results of a multicenter prospective study 48
Real-world comparison of safety profile in two groups of relapsing remitting multiple sclerosis on dimethyl-fumarate and teriflunomide therapy: preliminary results of a multicenter, prospective study 47
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 46
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey 43
Pharmacoeconomics of synthetic therapies for multiple sclerosis 41
A multimodal approach to distinguish multiple sclerosis phenotypes at diagnosis using biomarker profiles 40
Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 39
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series 39
New treatment targets in multiple sclerosis therapy 38
Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study 30
Positioning siponimod and the post-treatment gap: the unmet needs of SPMS patients in Italian real-world practice 29
Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab 23
Totale 4.173
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.908
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.908
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 24 0 1
2021/2022231 5 0 1 0 95 5 7 14 26 16 4 58
2022/2023722 60 18 39 47 14 44 2 37 413 19 17 12
2023/2024219 15 29 13 17 36 11 18 35 21 9 9 6
2024/20251.061 42 35 38 12 19 117 144 55 250 69 108 172
2025/20261.915 96 247 240 322 117 86 303 217 200 87 0 0
Totale 4.173